Red graphic with logos of companies featured in story

University of Utah startups continue innovating and discovering solutions to today’s unmet needs. Here’s a roundup of some of the latest news out of these companies:

Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

Myriad logo

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that the United States Patent and Trademark Office has issued a third patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market.

Read more about Myriad's patent

Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics

Myriad logo

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Ultima Genomics, Inc., a developer of a revolutionary new ultra-high throughput next-generation sequencing (NGS) platform, announced a joint effort to explore Ultima’s UG 100™ sequencing platform and its ppmSeq™ technology to advance Myriad’s ability to offer groundbreaking clinical tests. Myriad has purchased a new UG 100 that will soon join other leading sequencing platforms in its new Lab of the Future facility in South San Francisco.

Learn more about Myriad's news

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

Recursion logo

Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a Phase 1/2 clinical trial of REC-1245, a new chemical entity for the treatment of biomarker-enriched solid tumors and lymphoma.

Read about Recursion's latest development

Recursion hires new Chief People & Impact Officer

Recursion logo

Recursion announced that Erica Fox has joined the company as Chief People and Impact Officer where she will help deliver business goals while focusing on organizational productivity, engagement and growth, as well as Recursion’s broader social impact.

Learn more about Recursion's new Chief People & Impact Officer

Questions?

We support you and your innovation.

Wherever you are on your innovation journey, the Technology Licensing Office is your go-to source to connect you with the U’s innovation ecosystem.

Call 801.581.7792 or send us a message